• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Merck KGaA signs deal with Artios Pharma for cancer drugs research

expresspharmaDecember 07, 2020

Tag: Merck KGaA , Artios Pharma , Cancer

Germany’s Merck KGaA has signed a three-year strategic research deal with Artios Pharma to discover and develop up to eight potential targeted treatments for cancer.

Under the agreement, Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up to $860 million total milestones per target.

Merck said in a statement it will have the right to opt into exclusive development and commercialisation of compounds on up to eight targets.

Previous:Indifi forays into pharma segment along with Marg ERP

Next:Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Merck KGaA signs deal with Artios Pharma for cancer drugs research | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China
Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer

Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer
Hydroxypropyl beta cyclodextrin in the anticancer drug oxaliplatin

Hydroxypropyl beta cyclodextrin in the anticancer drug oxaliplatin
Anticancer Product Green tea Extract Powder. Tea Polyphenols

Anticancer Product Green tea Extract Powder. Tea Polyphenols

Paclitaxel semi-synthetic and natural USP cancer

Paclitaxel semi-synthetic and natural USP cancer
Natural red Chilly Seed oil with 1-10 Capsaicine for lower cholesterol and The prevention of cancer

Natural red Chilly Seed oil with 1-10 Capsaicine for lower cholesterol and The prevention of cancer

Toremifene citrate for Anticancer in China 99% GMP

Toremifene citrate for Anticancer in China 99% GMP
HPV E7(Cervical Cancer Biomarker) test Kit

HPV E7(Cervical Cancer Biomarker) test Kit
100% Pure Natural Anti-cancer Extraction Bitter Apricot Seed Extract

100% Pure Natural Anti-cancer Extraction Bitter Apricot Seed Extract

Nimustine hydrochloride 99%min Pharmaceutical API Nitrosourea drugs Anti cancer drugs made in china

Nimustine hydrochloride 99%min Pharmaceutical API Nitrosourea drugs Anti cancer drugs made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service